ARTHRITIS & RHEUMATISM Vol. 50, No. 8, August 2004, pp 2381–2386 DOI 10.1002/art.20468 © 2004, American College of Rheumatology Arthritis & Rheumatism An Ofﬁcial Journal of the American College of Rheumatology www.arthritisrheum.org and www.interscience.wiley.com EDITORIAL NF-B: Holy Grail for Rheumatoid Arthritis? Gary S. Firestein The transcription factor NF-B might be the Holy Grail of therapeutic targets for rheumatoid arthritis (RA). It serves as a “master switch” for an inflammatory cascade that encompasses many key genes involved in synovitis, including cytokines, metalloproteinases, and regulators of small-molecule mediators (1). NF-B suppression is demonstrably beneficial in a host of animal models of inflammatory disease, and many therapeutic agents, including corticosteroids, leflunomide, sulfasalazine, and aspirin, could mediate at least some of their effects through NF-B blockade. The creativity of diverse investigators driven to block this pathway is impressive, and has led to experiments using smallmolecule inhibitors of regulatory enzymes, gene therapy, decoy oligonucleotides, and various biologics. In this issue of Arthritis & Rheumatism, Blackwell and colleagues (2) describe a novel approach to inhibiting NF-B activation through the delivery of a fusion protein that includes components of the natural inhibitor of NF-B, called IB, and a viral-derived chaperone that escorts proteins through the plasma membrane into the cytoplasm. This novel approach suppresses local cytokine production and the influx of leukocytes into sites of inflammation. Inflammatory and immune responses, especially after activation of primitive pattern-recognition receptors by pathogens, are largely coordinated by NF-B (3). For instance, the transcription of many cytokine genes, including interleukin-6 (IL-6), IL-8, tumor necrosis factor ␣ (TNF␣), and IL-1␤, is initi- ated by NF-B activation. Induction of adhesion molecules on endothelial cells (vascular cell adhesion molecule 1 [VCAM-1], E-selectin, and intercellular adhesion molecule 1 [ICAM-1]) with recruitment of inflammatory cells to extravascular sites is also mediated by this transcription factor (4). NF- B– dependent tissue remodeling and increased vascular permeability through the expression of metalloproteinases, inducible nitric oxide synthase, and cyclooxygenase 2 contribute to local injury. Even antibody production and T cell–dependent delayed-type hypersensitivity use this pathway. NF-B is a complex group of heterodimeric and homodimeric transcription factors. Key members of this family include NF-B1 (p50/p105), NF-B2 (p52/p100), RelA (p65), RelB, and c-Rel. These molecules are trapped in the cytoplasm as an inactive complex by IB. Heterodimers containing p65 and either p50 or p52 are among the most frequently observed in various cell lineages and, when freed from IB, can initiate gene transcription through transactivating domains. Other combinations, such as p50 homodimers, exhibit negative regulatory effects on many genes. Cell activation through cytokine stimulation, engagement of Toll-like receptors (TLRs), or stress initiates a host-defense signaling pathway that can converge on an enzyme complex containing two IB kinases, known as IKK-1 and IKK-2 (also called IKK␣ and IKK␤, respectively), as well as a regulatory protein (IKK␥) that is required for IKK activation (5). Upstream kinases, including members of the MAPKKK family and NF-B–activating kinase (NAK), can phosphorylate the IKK signalsome and initiate the NF-B cascade (6). IKKs then phosphorylate IB␣ at serine 32 and serine 36 (or other IB isoforms at homologous amino acid residues), which targets the inhibitor for ubiquitination and degradation by the 26S proteasome. Gary S. Firestein, MD: University of California, San Diego School of Medicine. Address correspondence and reprint requests to Gary S. Firestein, MD, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0656. E-mail: email@example.com. Submitted for publication April 5, 2004; accepted in revised form May 12, 2004. 2381 2382 This process, initiated within minutes of surface receptor ligation, releases NF-B and leads to its nuclear translocation, followed by initiation of gene transcription. The specific genes that are activated depend on the various NF-B–binding sequences in promoter regions as well as the components of the NF-B dimers. IKK-2 is an absolute requirement for this pathway in many circumstances, especially those related to innate immunity, while the absence of IKK-1 in knockout mice typically has little effect on NF-B translocation. However, IKK-1 is an integral part of signaling through RANK, the receptor activator of NF-B (7). Defective IKK-1 activity has little effect on innate immune responses but is required for lymphoid development and T cell–dependent antibody responses (8). Other kinases, such as NF-B–inducing kinase, can be activated by lymphotoxin and signals via an alternative pathway that involves only IKK-1, with subsequent processing of NF-B1 to produce p52 dimers (9). The rate of IB degradation and resynthesis depends on a variety of factors, including the particular isoforms of IB expressed by each cell lineage. IB␣, which is commonly found in synovial macrophages and fibroblast-like synoviocytes, is rapidly degraded and then resynthesized within 1–2 hours. Resynthesis of IB␤ in other cells, however, is often delayed and leads to prolonged NF-B translocation (10). Degradation of IB⑀ is relatively slow, although this protein can be quickly resynthesized. The binding affinities of different IB isoforms for NF-B components also determine gene regulation. For instance, IB␣ and IB␤ bind to p65, but not to ␣ c-Rel; however, IB⑀ can associate with both (11). The p50/p65 heterodimer binds to IB␤ with greater avidity than do p50/RelB or p50/c-Rel dimers. These differences are clearly relevant to approaches designed to enhance IB expression, such as the TatsrIB␣ construct, when the variability in NF-B dimer components are observed. NF-B activation has been implicated in the pathogenesis of RA. As demonstrated by electromobility shift assays, NF-B binding is significantly higher in RA synovium compared with osteoarthritis synovium (12,13). Immunohistochemistry studies identify nuclear p50 and p65 translocation in the synovial lining and mononuclear cells of the sublining. In vitro studies confirm a role of NF-B in the production of cytokines by macrophages, as well as elevated constitutive production of IL-6 by RA synoviocytes (14). Animal models of RA also support the notion that NF-B participates in synovitis. Time-course studies in both murine collageninduced arthritis and rat adjuvant-induced arthritis dem- FIRESTEIN Figure 1. Potential therapeutic interventions designed to suppress nuclear factor B (NF-B) in arthritis. MAPKKK ⫽ mitogen-activated protein kinase kinase kinase; NAK ⫽ NF-B–activating kinase; IB ⫽ inhibitor of B; IKK ⫽ IB kinase; P ⫽ phosphate; U ⫽ ubiquitin. onstrate NF-B activation prior to the appearance of clinical disease (15). Selective activation of IKK-2 by intraarticular gene transfer leads to arthritis in rats, thus confirming that IKK activation is sufficient to initiate synovitis (16). Several commonly used therapeutic agents, most notably, corticosteroids, can suppress NF-B, but more selective inhibitors are clearly desirable in order to minimize NF-B–independent toxicity. Blockade of the IKK signal complex has attracted considerable attention based on its pivotal role in NF-B signaling and potential inhibition by small molecules (Figure 1). IKK-2 is an especially attractive target for therapy because it regu- EDITORIAL lates cytokine production in many cell types, including cultured synoviocytes. For example, a dominantnegative IKK-2 adenovirus construct almost completely abrogates cytokine-induced IL-6, IL-8, and ICAM-1 expression (17). Intraarticular gene therapy with dominant-negative IKK-2 in rats with adjuvant-induced arthritis decreases NF-B nuclear translocation and suppresses joint swelling. Although gene transfer has some advantages when considering local therapy, the development of small-molecule inhibitors of IKK-2 has contributed additional proof that this kinase is a potential target. Published data on 2 selective IKK-2 inhibitors demonstrate remarkable clinical efficacy in rat adjuvantinduced arthritis and murine collagen-induced arthritis (18,19). In addition to decreased inflammation, bone and cartilage destruction is also significantly lower in the animals treated with the IKK-2 inhibitors. Gene-transfer studies suggest that cytokine production by cultured rheumatoid synovial tissue cells is largely dependent on IKK-2 (20). However, production of some cytokines, such as TNF␣, is not blocked by dominant-negative IKK-2, indicating a substantial degree of complexity that was not anticipated. Information on the role of IKK-1 in arthritis is less robust, and this kinase plays little role in cytokine production by fibroblast-like synoviocytes. Endogenous peroxisome proliferator–activated receptor ␥ agonists, such as 5-deoxy-⌬12,14-prostaglandin J2, can also decrease inflammatory responses through inhibition of IKK and could serve as a normal counterregulatory response (21). While the early focus in arthritis has been on IKK-2, other signaling pathways that feed into NF-B also might be targeted. Upstream MAPKs, such as MEKK-1 or NAK, have potential, as do the IKK-related kinases inducible IKK (IKK-i) and TANK-binding kinase 1 (TBK-1) (22). The role of the latter two molecules in inflammation is only partially understood at the present time. Although IKK-i can recognize IB as a substrate, the process is inefficient, because only 1 of the 2 serines required for rapid degradation is phosphorylated. In contrast, the IKK-related kinases also participate in other pathways relevant to RA, including TLR signal transduction and expression of IL-6 and interferon-␤ (23). Little or no information is available on the pharmacology of IKK-related kinases in inflammation. Moving downstream from IKK, methods for stabilizing IB have been evaluated extensively in cell culture. Typically, genetic constructs that overexpress IB or an engineered protein that lacks the sites for 2383 phosphorylation (IB super-repressor) have been used. These proteins, although very effective in vitro, present major technical hurdles in vivo because they must enter the cells to be effective. In practice, this usually requires gene transfer using viral or nonviral vectors. Blackwell et al have added a very interesting twist to IB therapy by using a novel construct that allows the therapeutic protein to traverse cell membranes in order to reach the cytoplasm. In a rat model of pleurisy, they demonstrated that this fusion protein does, indeed, penetrate cells and forms a stable complex with NF-B that blocks activation. Even more striking, systemic administration inhibits leukocyte migration into the pleural space after injection with a proinflammatory stimulus. The mechanism appears to be related to enhanced apoptosis, probably due to loss of NF-B–mediated protection from cell death. In addition, cytokine and chemokine production in the pleural cavity are decreased and probably contribute to the antiinflammatory effect. The authors also noted that local administration of the protein has much less benefit than systemic exposure. One possible explanation is that circulating leukocytes are exposed to the construct after intravenous injection, thereby inducing apoptosis and preventing extrapleural cell activation that is required for cell migration. Alternatively, the primary effect could be on the vascular endothelium, where induction of adhesion molecules, such as VCAM-1, ICAM-1, and E-selectin, requires NF-B (24). Regardless of the mechanism, the results suggest that in this model of acute inflammation, systemic inhibition is necessary for the full benefit. The observation is consistent with the clinical efficacy of selective IKK-2 inhibitors in arthritis, which may be greater with systemic administration than with intraarticular gene therapy techniques. However, it is important to recognize the significant differences between acute inflammation, which is highly dependent on transient influx of neutrophils, and chronic disease, where the prominent infiltration of the synovium with longerlived mononuclear cells dominates. Furthermore, the pharmacokinetics of the Tat-srIB␣ protein after local injection still needs to be determined, and reformulation could improve efficacy. The Tat-srIB␣ approach is a technical tour de force and is unquestionably valuable as a proof-ofconcept experiment, but some questions should be answered to determine the utility of the construct as a therapeutic agent. For example, the dosing and frequency of administration need to be assessed for longterm administration. Although it is clear that the con- 2384 struct enters leukocytes, the distribution in other tissues and the toxicity are not defined. Some concerns about the role of NF-B inhibition in hepatocyte apoptosis need to be addressed, along with effects on other host responses to pathogens. These questions are not unique to Tat-srIB␣, but should be considered with any longterm therapy that inhibits NF-B. In addition to enhancing intracellular levels of IB by providing exogenous protein, efforts to prevent degradation of endogenous IB have been explored. For instance, inhibitors of E2 ubiquitin–conjugating enzymes could interfere with IB ubiquitination. Alternatively, one could target the proteasome to prevent degradation of IB after ubiquitination. One such compound, MG132, increases intracellular IB levels and, like Tat-srIB␣ and other NF-B–targeted approaches, induces synovial apoptosis in arthritis (25). One concern with this method is the multitude of proteins that are processed by ubiquitin and the proteasome, and toxicity could be a major hurdle. Interfering with NF-B binding and transactivating effects represents another post-IB targeting alternative. For instance, decoy oligonucleotides that contain an NF-B-binding site can be delivered into cells to prevent gene transcription (26). This approach is effective in rat streptococcal cell wall– induced arthritis, and the beneficial effects again appear to be related to induction of synovial apoptosis. Strategies to decrease the expression of specific NF-B proteins using antisense or RNA interference could selectively alter the gene expression patterns by changing the composition of NF-B dimers. Despite the abundant data indicating a key role of NF-B in inflammatory diseases, significant safety concerns about inhibition of this transcription factor remain. NF-B sits at the crossroads of host defense, homeostasis, cell survival, and response to stress, and there are major issues related to systemic inhibition of this primordial protective mechanism. Surely, a price will be paid for blocking the innate immune responses that begin with engagement of TLRs and result in NF-B–driven gene expression. Some anticipated defects in host defense have already been identified, such as increased susceptibility to infections such as Listeria monocytogenes (27). Equally important, the induction of apoptosis due to NF-B inhibition has significant potential for collateral damage to normal or physiologically stressed tissues. The most prominent example is florid hepatic apoptosis, which occurs in IKK-2– or RelA-knockout mice (28). This problem can be abrogated by suppressing TNF responses, as shown in TNF and RelA–double- FIRESTEIN knockout mice (29). TNF-dependent apoptosis is obviously relevant to diseases marked by increased production of TNF␣, such as RA, where the risks of NF-B blockade might be amplified. A similar doubleedged sword is apparent in mice lacking IKK-2 in gastrointestinal enterocytes. Although these animals are protected from systemic inflammatory responses after gut ischemia-reperfusion, the local mucosa is damaged by extensive apoptosis related to the lack of NF-B. Because IKK-2 plays an essential role in B cell development (30), inhibitors could have a significant impact on antibody production, germinal center formation, and lymphoid tissue maturation. The role of NF-B proteins in other normal immune responses and development also raises concerns. Abnormal antibody production is observed in p50-knockout mice, and absence of RelB interferes with the development of dendritic cells. In addition to B cell defects, osteoclast development has also been noted in p50 and p52–double-knockout mice (31). The use of small-molecule inhibitors of various kinases and regulatory proteins in the NF-B pathway also suffers from potential issues related to the specificity of the compound. It is difficult to design truly selective inhibitors because many bind to ATP-binding sites with significant homology across the universe of kinases. Screening for specificity against all possible targets, as well as other ATP- or substrate-binding sites, is problematic at best. Despite this, significant strides have been made in the chemistry of kinase inhibitors, and at least some specificity appears feasible. These issues are, of course, less critical with biologic agents such as Tat-srIB␣. How are we to approach NF-B under such circumstances? One goal could be to modulate, rather than completely ablate, NF-B function. Global inactivation of NF-B, such as with proteasome inhibitors, enhancement of cellular IB levels, or decoy oligonucleotides, could have the greatest potential for toxicity, although some selectivity based on cell-specific IB isoforms is possible. IKK-2 blockade suffers from many constraints as well, but there are clearly alternative pathways that permit some activation of NF-B. For example, one selective IKK-2 inhibitor, SC-514, suppresses and delays IB degradation but does not entirely block it (32). Even if IKK-2 were inhibited, IKK-1– and IKK-related kinase-mediated IB phosphorylation would remain intact, thereby permitting basal or stressinduced NF-B activation in some tissues. Other selective kinase-targeted approaches could potentially block pathogenic NF-B activation and inhibit macrophage EDITORIAL 2385 cytokine production while permitting basal or normal responses in other cell lineages. The use of biologics such as Tat-srIB␣ could achieve site and event specificity based on the method of delivery, the NF-B heterodimers and homodimers expressed, and the relative ability of the construct to enter different cell lineages. The jury is still out on the relative balance between the benefits and risks of NF-B blockade; we do not know if NF-B is the Holy Grail or a tantalizing and dangerous temptation. The recognition that RA is a serious disease with considerable morbidity and mortality helps pave the way for aggressive therapy, and we should not shy away from interventions that might provide a major positive impact on our patients’ lives. One recalls that worries about the dangers of anticytokine therapy contributed to considerable trepidation over a decade ago; it turns out that humans are remarkably resilient and adapt more readily than our murine brethren. Proof-of-concept in RA awaits while the multitude of NF-B–directed approaches move inexorably toward the clinic. REFERENCES 1. Li Q, Verma IM. NF-B regulation in the immune system. Nat Rev Immunol 2002;2:725–34. 2. Blackwell NM, Sembi P, Newson JS, Lawrence T, Gilroy DW, Kabouridis P. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IB␣ repressor. Arthritis Rheum 2004;50: 2675–84. 3. Baldwin AS Jr. The NF-B and IB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–83. 4. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IB-␣ phosphorylation. J Immunol 1995;155:3538–45. 5. Karin M, Yamamoto Y, Wang QM. The IKK NF-B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17–26. 6. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, et al. NAK is an IB kinase-activating kinase. Nature 2000;404:778–82. 7. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, et al. IKK␣ provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001;107:763–75. 8. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKK␣ of a second, evolutionary conserved, NF-B signaling pathway. Science 2001;293:1495–9. 9. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al. The lymphotoxin-␤ receptor induces different patterns of gene expression via two NF-B pathways. Immunity 2002;17: 525–35. 10. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IB-␤ regulates the persistent response in a biphasic activation of NF-B. Cell 1995;80:573–82. 11. Spiecker M, Darius H, Liao JK. A functional role of IB-⑀ in endothelial cell activation. J Immunol 2000;164:3316–22. 12. Han ZN, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197–208. 13. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-B in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762–70. 14. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-B and CBF1. Am J Pathol 1998;152:793–803. 15. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al. The effect of dexamethasone on the expression of activated NF-B in adjuvant arthritis. Clin Immunol Immunopathol 1997; 83:173–8. 16. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor B kinase ␤ is a key regulator of synovial inflammation. Arthritis Rheum 2001;44: 1897–907. 17. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein GS. NF-B regulation by IB kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001;166:2705–11. 18. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, et al. A highly selective inhibitor of IB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003;48: 2652–9. 19. Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003;62:1186–9. 20. Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, et al. Heterogeneous requirement of IB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003;48:1901–12. 21. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-⌬12,14-prostaglandin J2 inhibits multiple steps in the NF-B signaling pathway. Proc Natl Acad Sci U S A 2000;97: 4844–9. 22. Huynh QK, Kishore N, Mathialagan S, Donnelly AM, Tripp CS. Kinetic mechanisms of IB-related kinases (IKK) inducible IKK and TBK-1 differ from IKK-1/IKK-2 heterodimer. J Biol Chem 2002;277:12550–8. 23. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKK⑀ plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem 2003;278: 26612–9. 24. Li P, Sanz I, O’Keefe RJ, Schwarz EM. NF-B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 2000;164: 5990–7. 25. Kawakami A, Nakashima T, Sakai H, Hida A, Urayama S, Yamasaki S, et al. Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum 1999;42:2440–8. 26. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. NF-B activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 1998;95:13859–64. 27. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-B leads to multifocal defects in immune responses. Cell 1995;80:321–30. 28. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, et al. Embryonic lethality, liver degeneration, and impaired NF-B activation in IKK-␤-deficient mice. Immunity 1999;10:421–9. 29. Doi TS, Marino MW, Takahashi T, Yoshida T, Sakakura T, Old LJ, et al. Absence of tumor necrosis factor rescues RelA-deficient 2386 mice from embryonic lethality. Proc Natl Acad Sci U S A 1999;96:2994–9. 30. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IB kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002;196:743–52. 31. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, et al. NF-B p50 and p52 expression is not required for RANK- FIRESTEIN expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002;17:1200–10. 32. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, et al. A selective IKK-2 inhibitor blocks NF-B-dependent gene expression in interleukin-1 ␤-stimulated synovial fibroblasts. J Biol Chem 2003;278:32861–71.